Annual EBITDA
-$427.43 M
-$49.69 M-13.15%
31 December 2023
Summary:
Iovance Biotherapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$427.43 million, with the most recent change of -$49.69 million (-13.15%) on 31 December 2023. During the last 3 years, it has fallen by -$174.21 million (-68.80%). IOVA annual EBITDA is now -2968177.78% below its all-time high of -$14.40 thousand, reached on 31 December 2009.IOVA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$77.92 M
+$13.13 M+14.42%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$77.92 million, with the most recent change of +$13.13 million (+14.42%) on 30 September 2024. Over the past year, it has increased by +$30.57 million (+28.18%). IOVA quarterly EBITDA is now -1638.90% below its all-time high of $5.06 million, reached on 31 December 2012.IOVA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$388.33 M
+$30.57 M+7.30%
30 September 2024
Summary:
Iovance Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$388.33 million, with the most recent change of +$30.57 million (+7.30%) on 30 September 2024. Over the past year, it has increased by +$28.89 million (+6.93%). IOVA TTM EBITDA is now -9576.22% below its all-time high of $4.10 million, reached on 31 March 2013.IOVA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -13.2% | +28.2% | +6.9% |
| 3 y3 years | -68.8% | +5.3% | -31.9% |
| 5 y5 years | -235.8% | -51.9% | -121.2% |
IOVA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -68.8% | at low | at high | +30.1% | -31.9% | +9.7% |
| 5 y | 5 years | -235.8% | at low | -51.9% | +30.1% | -121.2% | +9.7% |
| alltime | all time | <-9999.0% | at low | -1638.9% | +30.1% | -9576.2% | +9.7% |
Iovance Biotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$77.92 M(-14.4%) | -$388.33 M(-7.3%) |
| June 2024 | - | -$91.05 M(-15.5%) | -$418.89 M(-2.6%) |
| Mar 2024 | - | -$107.81 M(-3.3%) | -$430.09 M(+0.6%) |
| Dec 2023 | -$427.43 M(+13.2%) | -$111.54 M(+2.8%) | -$427.43 M(+2.4%) |
| Sept 2023 | - | -$108.49 M(+6.1%) | -$417.22 M(+3.3%) |
| June 2023 | - | -$102.25 M(-2.8%) | -$403.93 M(+2.0%) |
| Mar 2023 | - | -$105.16 M(+3.8%) | -$396.17 M(+4.9%) |
| Dec 2022 | -$377.74 M(+14.9%) | -$101.33 M(+6.4%) | -$377.74 M(+1.7%) |
| Sept 2022 | - | -$95.19 M(+0.7%) | -$371.42 M(+3.6%) |
| June 2022 | - | -$94.49 M(+8.9%) | -$358.50 M(+4.6%) |
| Mar 2022 | - | -$86.73 M(-8.7%) | -$342.66 M(+4.2%) |
| Dec 2021 | -$328.72 M(+29.8%) | -$95.00 M(+15.5%) | -$328.72 M(+11.7%) |
| Sept 2021 | - | -$82.28 M(+4.6%) | -$294.36 M(+8.7%) |
| June 2021 | - | -$78.65 M(+8.0%) | -$270.75 M(+6.0%) |
| Mar 2021 | - | -$72.80 M(+20.0%) | -$255.46 M(+0.9%) |
| Dec 2020 | -$253.22 M(+27.4%) | -$60.64 M(+3.4%) | -$253.22 M(+1.1%) |
| Sept 2020 | - | -$58.66 M(-7.4%) | -$250.45 M(+3.0%) |
| June 2020 | - | -$63.37 M(-10.2%) | -$243.08 M(+5.9%) |
| Mar 2020 | - | -$70.56 M(+21.9%) | -$229.59 M(+15.5%) |
| Dec 2019 | -$198.75 M(+56.1%) | -$57.86 M(+12.8%) | -$198.75 M(+13.2%) |
| Sept 2019 | - | -$51.30 M(+2.8%) | -$175.58 M(+10.4%) |
| June 2019 | - | -$49.88 M(+25.6%) | -$159.09 M(+13.3%) |
| Mar 2019 | - | -$39.72 M(+14.5%) | -$140.37 M(+10.3%) |
| Dec 2018 | -$127.30 M(+38.5%) | -$34.69 M(-0.3%) | -$127.30 M(+7.5%) |
| Sept 2018 | - | -$34.81 M(+11.7%) | -$118.44 M(+12.0%) |
| June 2018 | - | -$31.15 M(+16.9%) | -$105.73 M(+8.0%) |
| Mar 2018 | - | -$26.65 M(+3.2%) | -$97.91 M(+6.5%) |
| Dec 2017 | -$91.92 M(+74.6%) | -$25.83 M(+16.9%) | -$91.92 M(+12.5%) |
| Sept 2017 | - | -$22.10 M(-5.3%) | -$81.73 M(+4.2%) |
| June 2017 | - | -$23.34 M(+13.0%) | -$78.46 M(+17.8%) |
| Mar 2017 | - | -$20.66 M(+32.2%) | -$66.58 M(+26.4%) |
| Dec 2016 | -$52.66 M | -$15.63 M(-17.0%) | -$52.66 M(+16.5%) |
| Sept 2016 | - | -$18.83 M(+64.4%) | -$45.20 M(+33.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$11.46 M(+69.9%) | -$33.74 M(+18.4%) |
| Mar 2016 | - | -$6.74 M(-17.5%) | -$28.49 M(+6.1%) |
| Dec 2015 | -$26.86 M(+124.7%) | -$8.17 M(+10.8%) | -$26.86 M(+14.3%) |
| Sept 2015 | - | -$7.38 M(+19.0%) | -$23.49 M(+24.2%) |
| June 2015 | - | -$6.20 M(+21.3%) | -$18.91 M(+27.6%) |
| Mar 2015 | - | -$5.11 M(+6.5%) | -$14.82 M(+24.0%) |
| Dec 2014 | -$11.95 M(-47.2%) | -$4.80 M(+71.7%) | -$11.95 M(-35.9%) |
| Sept 2014 | - | -$2.80 M(+32.7%) | -$18.65 M(-26.2%) |
| June 2014 | - | -$2.11 M(-6.0%) | -$25.25 M(-4.6%) |
| Mar 2014 | - | -$2.24 M(-80.5%) | -$26.47 M(+6.2%) |
| Dec 2013 | -$22.63 M(+2467.7%) | -$11.50 M(+22.2%) | -$24.93 M(+197.8%) |
| Sept 2013 | - | -$9.41 M(+183.0%) | -$8.37 M(-1805.2%) |
| June 2013 | - | -$3.32 M(+372.8%) | $490.90 K(-88.0%) |
| Mar 2013 | - | -$703.00 K(-113.9%) | $4.10 M(-564.7%) |
| Dec 2012 | -$881.50 K(-95.7%) | $5.06 M(-1028.4%) | -$881.80 K(-90.4%) |
| Sept 2012 | - | -$545.40 K(-292.7%) | -$9.18 M(-36.3%) |
| June 2012 | - | $283.00 K(-105.0%) | -$14.40 M(-42.9%) |
| Mar 2012 | - | -$5.68 M(+75.8%) | -$25.22 M(+25.0%) |
| Dec 2011 | -$20.54 M(+2614.0%) | -$3.23 M(-44.0%) | -$20.18 M(+16.1%) |
| Sept 2011 | - | -$5.77 M(-45.3%) | -$17.39 M(+47.5%) |
| June 2011 | - | -$10.54 M(+1547.0%) | -$11.79 M(+786.7%) |
| Mar 2011 | - | -$640.10 K(+45.5%) | -$1.33 M(+75.6%) |
| Dec 2010 | -$756.80 K(+5155.6%) | -$440.00 K(+167.2%) | -$757.00 K(+137.3%) |
| Sept 2010 | - | -$164.70 K(+94.7%) | -$319.00 K(+102.7%) |
| June 2010 | - | -$84.60 K(+25.0%) | -$157.40 K(+107.7%) |
| Mar 2010 | - | -$67.70 K(+3285.0%) | -$75.80 K(+426.4%) |
| Dec 2009 | -$14.40 K(-74.2%) | -$2000.00(-35.5%) | -$14.40 K(-45.5%) |
| Sept 2009 | - | -$3100.00(+3.3%) | -$26.40 K(+3.9%) |
| June 2009 | - | -$3000.00(-52.4%) | -$25.40 K(-31.5%) |
| Mar 2009 | - | -$6300.00(-55.0%) | -$37.10 K(-33.5%) |
| Dec 2008 | -$55.80 K | -$14.00 K(+566.7%) | -$55.80 K(+33.5%) |
| Sept 2008 | - | -$2100.00(-85.7%) | -$41.80 K(+5.3%) |
| June 2008 | - | -$14.70 K(-41.2%) | -$39.70 K(+58.8%) |
| Mar 2008 | - | -$25.00 K | -$25.00 K |
FAQ
- What is Iovance Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual EBITDA year-on-year change?
- What is Iovance Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly EBITDA year-on-year change?
- What is Iovance Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM EBITDA year-on-year change?
What is Iovance Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of IOVA is -$427.43 M
What is the all time high annual EBITDA for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$14.40 K
What is Iovance Biotherapeutics annual EBITDA year-on-year change?
Over the past year, IOVA annual earnings before interest, taxes, depreciation & amortization has changed by -$49.69 M (-13.15%)
What is Iovance Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of IOVA is -$77.92 M
What is the all time high quarterly EBITDA for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $5.06 M
What is Iovance Biotherapeutics quarterly EBITDA year-on-year change?
Over the past year, IOVA quarterly earnings before interest, taxes, depreciation & amortization has changed by +$30.57 M (+28.18%)
What is Iovance Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of IOVA is -$388.33 M
What is the all time high TTM EBITDA for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $4.10 M
What is Iovance Biotherapeutics TTM EBITDA year-on-year change?
Over the past year, IOVA TTM earnings before interest, taxes, depreciation & amortization has changed by +$28.89 M (+6.93%)